Recommendations in managing patients with nonvariceal upper gastrointestinal bleeding were recently updated, addressing resuscitation, risk assessment and pre-endoscopic care, endoscopy, pharmacotherapy, and secondary prophylaxis. Initial adequate resuscitation and risk stratification using validated scales remain critical. Intravenous erythromycin improves visualization when likely to find blood in the stomach. Pre-endoscopic proton pump inhibition (PPI) does not improve outcomes, but downstages high-risk endoscopic lesions and may be considered. In patients on anticoagulants, correction of a coagulopathy is recommended, but should not delay early endoscopy (within 24 h), as it improves clinical outcomes. In patients with high-risk endoscopic stigmata, although better than doing nothing, epinephrine injection alone provides suboptimal efficacy and should be combined with another modality such as clips, thermal or sclerosant injection, which are also efficacious alone. Following an attempt at dislodgment, adherent clots can be treated with high-dose intravenous PPI infusion alone (80 mg bolus and 8 mg/h for 3 days) or following endoscopic hemo stasis. The combination is indicated for all other patients with high-risk stigmata as there is currently a lack of high-quality generalizable data supporting other intravenous or oral PPI regimens. A second-look endoscopy is recommended only selectively after endoscopic hemo stasis. A negative Helicobacter pylori test requires confirmation in the acute setting. Following appropriate discussions, acetylsalicylic acid (ASA) can soon be restarted acutely after bleeding; long-term PPI co-therapy is imperative in patients having bled on nonsteroidal anti-inflammatory drugs if still needed (preferably with a cyclooxygenase-2, if appropriate) or ASA (not clopidogrel alone). Further work is needed to implement and disseminate these recommendations.
Introduction
Upper gastrointestinal bleeding (UGIB) represents a substantial economic and clinical burden, with incidence ranging from 48 to 160 cases per 100,000 adults per year, and mortality ranging from 10% to 14%. 1 A multidis ciplinary group of 34 experts from 15 countries met in late 2008 to develop inter national guide lines to help clinicians in making informed deci sions regarding the optimal management of pa tients who present with nonvariceal UGIB. These consensus recommendations were subsequently published in early 2010. The guidelines are sum marized below.
Recommendations relating to initial resuscitation of the patient Upon presentation, appropriate ini tial resuscitation should precede any further diag nostic measures. Initial resuscitation includes sta bilization of blood pressure and adequate restora tion of intravascular volume. Patients with hemo globin levels of 70 g/l or less should be adminis tered blood transfusions to increase hemo globin levels to the range of 70 to 90 g/l in the absence of coronary artery disease, tissue hypoperfusion, or acute hemo rrhage.
1 A greater target hemo globin level may be required in patients with cardiorespi ratory morbidities. In patients receiving antico agulants, correction of coagulopathy should be
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A summary of recent recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding Joshua Greenspoon, Alan Barkun in patients with nonvariceal bleeding. 1 The selec tive use of these agents can be considered for pa tients with massive unresponsive bleeding. They are indicated, of course, in the management of patients with variceal bleeding in conjunction with endoscopic ligation, 7 but this indication was outside the scope of the Consensus document. Promotility agents are not promoted for routine use; however, patients suspected of having large amounts of blood or clots in the stomach or who have recently eaten should receive a prokinet ic agent to improve visualization. 1 The adminis tration of a proton pump inhibitor (PPI) prior to endoscopy should be considered as it downstag es the bleeding lesion and decreases the need for endoscopic inter vention. 1 Although administra tion of pre endoscopic PPIs has not been shown to affect rates of rebleeding, surgery, or mortali ty, recent evidence has suggested that PPIs may have beneficial bio logical properties. 8 The most costeffective scenarios in which preendoscop ic PPI use may be administered include treating a patient likely to be bleeding from a nonvariceal source, especially if it is likely to be a highrisk le sion, and if a delay to early endoscopy is likely to occur. 1 TAbLE 3 summarizes the role of pharmaco logical agents in nonvariceal UGIB.
Endoscopic therapy Early endoscopy, defined as within the 24 hours following presentation, should be performed when possible, because ear ly endoscopy is associated with improved patient outcomes, and, consequently, reductions in length of hospitalization for both low and highrisk pa tients compared with delayed endoscopy.
1 Endos copy may need to be delayed in rare patients, in cluding those with suspected perforation or ac tive acute coronary syndrome. Patients classified at very low risk for rebleeding may be discharged home immediately after an early endoscopy. Both this latter group and those patients exhibiting lowrisk stigmata at endoscopy do not require en doscopic therapy and can be put on a single dai ly dose oral PPI; more complete postendoscopic pharmaco logical management is discussed below. All patients exhibiting highrisk lesions should re ceive endoscopic hemo stasis.
Various endoscopic hemo static techniques are available for use, including injection, thermoco agulation, and the use of clips. When a highrisk considered. A baseline inter national normalized ratio (INR) less than 1.3 vs. 1.3 or greater does not predict mortality, surgery, rebleeding, trans fusion requirements, or length of stay 2 suggest ing that it is not necessary to delay endoscopic therapy unless the INR (or prothtrombin time) is supratherapeutic. The reader is cautioned that for patients with cirrhosis, neither the INR nor the prothrombin time have been shown to ac curately predict the risk of bleeding; 3 therefore, the approach suggested above should not be ap plied to these patients.
Early risk stratification and initial management
Placement of a nasogastric tube should be con sidered in patients, as the presence of blood in the nasogastric aspirate confirms an upper gas trointestinal source.
4
Prognostic scales should be used to stratify pa tients into high and lowrisk categories for re bleeding and mortality.
1 Important clinical pre dictors of rebleeding and mortality include comor bid illness, low initial hemo globin levels, trans fusion requirements, finding of fresh red blood upon rectal examination or nasogastric aspirate or in the emesis, age over 65 years, and poor over all health status (TAbLE 1) . Endoscopic predictors of increased risk of rebleeding and mortality in clude active bleeding, ulcer size larger than 2 cm, ulcer location, and the presence of high risk stig mata (TAbLE 2) . 1 High risk lesions include those actively spurting (Forrest class IA) or oozing of blood (IB), a nonbleeding visible vessel (IIA), and adherent clots (IIB). Lowrisk lesions include flat, pigmented spots (grade IIC) and cleanbase ul cers (grade III). The Blatchford or preendoscop ic Rockall score (based on age, comorbidity, and the presence or absence of hemo dynamic insta bility) should initially be used to aid in stratifica tion and in determining which patients require ur gent endoscopy, or conversely, suitability for ear ly discharge. The complete Rockall score should be used at endoscopy (add to the clinical Rock all score the nature and appearance of the bleed ing lesion), as this score best identifies patients at low risk. 5 Neither somatostatin nor octreotide have been found in contemporary summary analyses to improve patient outcomes compared with other pharmacotherapy or endoscopic therapy, 6 and are therefore not recommended for routine use should be considered on a casebycase basis, if the effectiveness of endoscopic hemo stasis is in question or for patients at particularly high risk for rebleeding. The principles of endoscopic man agement are listed in Intravenous PPIs achieve more profound and sustained acid suppression than H 2 RA without the development of tolerance. [21] [22] [23] Metaanalyses 24,25 have confirmed that administration of highdose (80 mg bolus + 8 mg/h for 72 h) intravenous PPI to highrisk patients reduces the rate of rebleed ing, surgery, and, in patients having undergone successful endoscopic therapy, even mortality. Lowdose intravenous regimens may be as effec tive as the high dose, yet more definitive evidence showing equivalence between the 2 regimens is necessary before a lowdose regimen can be rec ommended. 1 Few headtohead gastric pH studies or clinical trials comparing oral and intravenous routes have been conducted; thus, conclusions re garding the effectiveness of oral PPI administration cannot be drawn at this time, although highdose oral PPI has been shown effective in Asian patients. These benefits are unclear in a Caucasian popula tion owing to differences in pharmacokinetics, pa rietal cell mass, Helicobacter pylori (H. pylori) car riage rates, and overall disease acuity of enrolled patients. Current consensus guidelines recom mend the intravenous highdose regimen to re duce rebleeding and mortality among highrisk endoscopic stigma is noted, although better than doing nothing, epinephrine injection alone pro vides suboptimal efficacy and should be used in combination with another modality such as clips, thermal or sclerosant injection, which are also ef ficacious alone. 10, 11 Endoscopists should opt for an efficacious hemo static method that they are most comfortable with. Finding a clot in an ulcer bed requires an attempt at dislodgement in or der to treat the underlying lesion. Optimal treat ment of adherent clots remains controversial; en doscopic therapy should be considered but high dose intravenous PPI therapy may be sufficient. 1 Routine secondlook endoscopy is not recom mended. 1 Two metaanalyses 12,13 had suggest ed marginal benefits in rebleeding rates; howev er, these analyses had significant methodo logical limitations and included trials in which patients were not treated in accordance with contempo rary clinical guidelines. Secondlook endoscopy Low-dose intravenous regimens may be as effective as the high dose, yet more definitive evidence showing equivalence between the 2 regimens is needed before a low-dose regimen can be recommended.
High-dose oral PPI can be considered in Asian populations.
PPI use upon discharge All patients should be discharged on an oral PPI with dosage and duration dependent on the underlying etiology to decrease the risk of rebleeding.
Abbreviations: PPI - proton pump inhibitor
TAbLE 4 Endoscopic principles of management in nonvariceal upper gastrointestinal bleeding
Endoscopy should be performed within the 24 hours that follow presentation when possible.
All patients exhibiting high-risk endoscopic stigmata should receive endoscopic hemo stasis.
Highly selected patients at very low risk for rebleeding (see TAbLE 5 for selection criteria) may be discharged home immediately after an early endoscopy.
Patients exhibiting a pigmented dot or clean base ulcer do not require endoscopic hemo stasis.
Although better than doing nothing, epinephrine injection alone provides suboptimal efficacy and should be used in combination with another modality such as clips, thermal or sclerosant injection that are also efficacious alone.
Endoscopists should opt for an efficacious hemo static method, with which they are most comfortable.
Finding a clot in an ulcer bed requires an attempt at dislodgement in order to treat the underlying lesion.
Optimal treatment of adherent clots remains controversial; endoscopic therapy should be considered but intensive intravenous PPI therapy may be sufficient.
Second-look endoscopy should be considered on a case-by-case basis if the effectiveness of endoscopic hemo stasis is in question or for patients at particularly high risk of rebleeding.
discharge and subsequent pharmaco logical management Randomized clinical trials of highly se lected patients at very low risk for rebleeding 1, 29 found no difference in outcomes with a policy of very early discharge. Criteria for such early dis charge include the finding of a clean ulcer base, adequate sociofamily support at home, accessibil ity to a hospital, and initial hemo dyamic stability. Additional selection criteria are listed in TAbLE 5 .
Patients are not suitable for early discharge if they exhibit serious comorbid illness, have an endo scopic finding of highrisk stigmata as defined pre viously, are hemo dynamically unstable, or have undesirable sociofamily conditions. 9 All patients should be discharged on an oral PPI with dosage and duration dependent on the underlying etiology to decrease the risk of rebleeding. 1 H. Pylori should be tested for with subsequent eradication if positive, with subsequent confirma tion of eradication. Due to tendency of H. pylori diagnostic tests to produce false negative results in the acute setting, a negative test should be re peated outside the acute setting. Patients having experienced a bout of nonvariceal UGIB while on a nonsteroidal antiinflammatory drug (NSAID) require discontinuation of the NSAID or should be put on a COX2 inhibitor (if no contraindica tion to its use) and a PPI since this combination is associated with a decreased risk of rebleed ing compared to the combination of a tradition al NSAID and PPI or cyclooxygenase2 inhibitor alone. 1 Patients requiring lowdose acetylsalicyl ic acid (ASA) should resume taking ASA as soon as the cardiovascular risks outweigh the risk of rebleeding.
1 This could be as early as 5 days after the onset of bleeding and should be determined after appropriate discussions with all health care professionals involved in the management of the patient. A patient who has had an episode of nonvariceal UGIB while taking ASA and who still requires cardioprotection should be prophy laxed with a PPI as the risk of bleeding persists if switched to clopidogrel alone. 1 In patients hav ing bled on clopidogrel and who are thus at a very high risk for rebleeding, the benefits of the PPI secondary prophylaxis is likely to outweigh any risk attributable to a clopidogrelPPI inter action with regards to cardiovascular events.
Rebleeding In cases of rebleeding, a second at tempt at endoscopic therapy is recommended to reduce the need for surgery.
1 In patients having failed endoscopic therapy, surgery should be con sidered.
1 If available, percutaneous embolization can be considered as an alternative to surgery. summary This brief review attempts to summa rize the main recommendations recently put for ward by an expert group. 1 The guidelines outline general management principles that may need to be individualized and adapted after involvement of the entire healthcare management team, es pecially considering the increasing complexity of patients. 1 An important point to remember is that if the patient was administered an 80 mg bolus pri or to endoscopy, the patient need not receive an other bolus after endoscopic therapy.
In-hospital management issues Patients consid ered at low risk for rebleeding after endoscopy can be fed within 24 hours.
1 Certain patients, in cluding those found to be bleeding from a Mallory Weiss tear or an ulcer exhibiting a clean base, flat spot, may be discharged within 24 hours. Most highrisk lesions require approximately 72 hours to evolve into a lowrisk appearance after endo scopic therapy, and several trials 26-28 have con firmed that most rebleeding (approximately 80%) in high risk patients occurs within the first 72 hours. Consequently, it is recommended that pa tients with highrisk stigmata be hospitalized for the full 72 hours of highdose intravenous PPI therapy following endoscopic hemo stasis. A negative H. pylori diagnostic test should be repeated outside the acute setting.
Patients having experienced a bout of nonvariceal UGIB while on an NSAID require discontinuation of the NSAID or should be put on a COX-2 inhibitor (if no contraindication to its use) and a PPI, because this combination is associated with a decreased risk of rebleeding compared to the combination of a traditional NSAID and PPI or COX-2 inhibitor alone.
Patients requiring low-dose ASA should resume taking ASA as soon as the cardiovascular risks outweigh the risk of rebleeding.
A patient who has had an episode of nonvariceal UGIB while taking ASA, and who still requires cardioprotection, should be prophylaxed with a PPI, because the risk of bleeding persists if switched to clopidogrel alone.
Abbreviations: ASA - acetylsalicylic acid, COX-2 - cyclooxygenase-2, H. TAbLE 3   TAbLE 7 The management of patients with nonvariceal upper gastrointestinal bleeding who experience a rebleeding episode
pyloriHelicobacter pylori, NSAID - nonsteroidal anti-inflammatory drugs, others - see
In cases of rebleeding, a second attempt at endoscopic therapy is recommended to reduce the need for surgery.
In patients having failed endoscopic therapy, surgery should be considered.
If available, percutaneous embolization can be considered as an alternative to surgery.
affected patients. As new research is performed, it is anticipated that the current guidelines will need updating, and the reader is encouraged to keep abreast of evolving literature in this im portant area.
